UK industry leaders call for reform to outdated R&D tax rules 19 February 2021 | By Victoria Rees (Drug Target Review) A report has been backed by eight industry leaders who say that updating R&D tax credit systems in the UK would release £4 billon of growth every year.
NAD depletion by IFN sensitises pancreatic cancer to NAMPT inhibition, study shows 19 February 2021 | By Victoria Rees (Drug Target Review) High IFN signalling in pancreatic tumours are sensitive to NAMPT inhibitors which block a pathway in NAD synthesis, presenting a drug target.
D614G Spike mutation makes SARS-CoV-2 up to eight times more infectious 18 February 2021 | By Victoria Rees (Drug Target Review) A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
LEAP proton therapy could target cancer cells that resist treatment 18 February 2021 | By Victoria Rees (Drug Target Review) A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Engineered peptide protects ferrets against SARS-CoV-2 transmission, study shows 18 February 2021 | By Victoria Rees (Drug Target Review) A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
New nanotherapy could potential treat Crohn’s disease in children 18 February 2021 | By Victoria Rees (Drug Target Review) A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
New drug combination could combat Diffuse Intrinsic Pontine Glioma 17 February 2021 | By Victoria Rees (Drug Target Review) The drug combination of difluoromethylornithine and AMXT 1501 has shown success against Diffuse Intrinsic Pontine Glioma in animal models.
RNA sequencing reveals insight into tuberculosis infection 17 February 2021 | By Victoria Rees (Drug Target Review) Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
Targeting Nsp1 protein could be a pathway for COVID-19 therapy 17 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
Experimental vaccine against synthetic opioids shows success in mice 17 February 2021 | By Victoria Rees (Drug Target Review) A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
Mutations in SARS-CoV-2 Spike could lead to greater infectivity, study shows 16 February 2021 | By Victoria Rees (Drug Target Review) Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
β-cell regeneration discovery could pave way for diabetes treatments 16 February 2021 | By Victoria Rees (Drug Target Review) A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.
Researchers discover process viruses use to block antiviral immune response 16 February 2021 | By Victoria Rees (Drug Target Review) A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
Machine learning identifies drugs to repurpose against COVID-19 15 February 2021 | By Victoria Rees (Drug Target Review) A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
Revealed protein structure could aid in Huntington’s disease treatment development 15 February 2021 | By Victoria Rees (Drug Target Review) Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
